Urol. praxi. 2019;20(3):102-107 | DOI: 10.36290/uro.2019.056

Perspectives of treatment of overactive bladder syndrome

MUDr. Miroslava Ryšánková
Urologická klinika, Fakultní nemocnice Hradec Králové

Overactive bladder syndrome (OAB) is a common disease of urological practice. Its treatment is extensive and includes both conservative treatment and medication and, after the failure of all these treatment, the surgical modality is indicated. However, proper diagnosis of the disease is essential for the treatment itself. Often, under the OAB, lower urinary tract symptoms are hidden behind benign prostatic hyperplasia (BHP), or, on the contrary, OAB hides behind irritative and obstructive symptoms of BPH. Medicamentous treatment remains the main treatment, and in recent years combination therapy has been very modern.

Keywords: overactive bladder, anticholinergic medication, LUTS

Published: July 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ryšánková M. Perspectives of treatment of overactive bladder syndrome. Urol. praxi. 2019;20(3):102-107. doi: 10.36290/uro.2019.056.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6): 1306-1315. Go to original source... Go to PubMed...
    2. Kaplan SA, Roehrborn CG, Gong J, et al. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving ?-blocker treatment for lower urinary tract symptoms. BJU Int. 2012; 109(12): 1831-1840. Go to original source... Go to PubMed...
    3. Oslander JG, Schapira M, Schnelle JF, et al. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? Ann Intern Med, 1995; 122: 749-754. Go to original source... Go to PubMed...
    4. El Din KE, Kiemeney LA, de Wildt MJ, et al. The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J Urol, 1996; 156: 1020-1025. Go to original source... Go to PubMed...
    5. Kaplan SA, Dmochowski R, Cash BD, et al. Systematic review of the relationship between bladder and bowel function: implications for patient management. Int J Clin Pract, 2013; 67: 205-216. Go to original source... Go to PubMed...
    6. Hannestad YS, Rortveit G, Daltveit AK, et al. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG, 2003; 110: 247-254. Go to original source...
    7. Rai BP, Cody JD, Alhasso A, et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev, 2012; 12: CD003193. Go to original source... Go to PubMed...
    8. Vodusek DB, Light JK, Libby JM. Detrusor inhibition induced by stimulation of pudendal nerve afferents. Neurourol Urodyn, 1986; 5: 381-389. Go to original source...
    9. Hagerty JA, Richards I, Kaplan WE. Intravesical electrotherapy for neurogenic bladder dysfunction: a 22-year experience. J Urol, 2007; 178: 1680-1683. Go to original source... Go to PubMed...
    10. Iyer S, Laus K, Rugino A, et al. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. Int Urogynecol J. 2018; 22. Go to original source... Go to PubMed...
    11. Shamliyan T, Wyman J, Kane RL, et al. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. 2012, IUGA-ICS Conservative Management for Female Pelvic Floor Dysfunction: Rockville (MD). Agency for Healthcare Research and Quality (US); 2012; 11(12): -EHC074-EF. Go to original source... Go to PubMed...
    12. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol, 2008. 54: 543-562. Go to original source... Go to PubMed...
    13. Verner P. Porovnání účinnosti a vedlejších účinků anticholinergik při léčbě OAB. Urolog. Praxi, 2010; 11(5): 241-246.
    14. Wagg A, Dale M, Tretter R, et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol, 2013. 64: 74-81. Go to original source... Go to PubMed...
    15. Sand PK, Johnson Ii TM, Rovner ES, et al. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged >/= 75 years) with overactive bladder syndrome. BJU Int, 2011; 107: 612-620. Go to original source... Go to PubMed...
    16. Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn, 2014; 33: 17-30. Go to original source... Go to PubMed...
    17. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol, 2013; 63: 296-305. Go to original source... Go to PubMed...
    18. Yoshida M, Takeda M, Gotoh M, et al. Efficacy of novel ?3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. Int J Urol. 2019; 26(3): 369-375. Go to original source... Go to PubMed...
    19. Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial. Eur Urol. 2019; 75(2): 274-282. Go to original source... Go to PubMed...
    20. Wang CJ, Lin YN, Huang SW, et al. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. J Urol, 2011; 185: 219-223. Go to original source... Go to PubMed...
    21. El-Zawahry A. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB). Curr Urol Rep. 2019; 20(6): 33. Go to original source... Go to PubMed...
    22. Gallegos PJ, Frazee LA. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy 2008; 28: 356-365. Go to original source... Go to PubMed...
    23. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled trial. J Urol 2003; 58: 2253-2256. Go to original source... Go to PubMed...
    24. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized. controlled multicenter study. Urol 2005; 174: 1334-1338. Go to original source... Go to PubMed...
    25. Matsuo T, Miyata, Y, Kakoki K, et al. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with alpha1-adrenergic receptor blocker monotherapy: Prospective analysis of elderly men. BMC Urol, 2016. 16: 45. Go to original source... Go to PubMed...
    26. Schurch B, Stöhrer M, Kramer G, et al. Botulinum - a-toxin for treating detrusor hyperreflexia in spinal cord injured patiens: a new alternative to anticholinergic drugs? Preliminary results. J Urol, 2000; 164: 692-699. Go to original source... Go to PubMed...
    27. Nitti VW, Dmochowski, R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol, 2013. 189: 2186-2193. Go to original source... Go to PubMed...
    28. Marinkovic SP. New technologies in the management of overactive bladder: current research and future prospects. Ther Adv Urol. 2019; 25; 11: eCollection 2019 Jan-Dec. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.